Palisade Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PALI research report →
Range $2 – $7
Price Chart
About the company
Palisade Bio, Inc. , a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease.
- CEO
- J. D. Finley
- IPO
- 2007
- Employees
- 14
- HQ
- Denver, CA, US
Get TickerSpark's AI analysis on PALI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $258.63M
- P/E
- -2.80
- PEG
- -0.01
- P/S
- 517.27
- P/B
- 2.59
- EV/EBITDA
- -4.02
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -7069.80%
- Net Margin
- -6388.20%
- ROE
- -33.47%
- ROIC
- -28.96%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,056,000
- Net Income
- $-16,781,000-16.2%
- EPS
- $-0.30+97.1%
- OCF Growth
- +11.0%
- FCF Growth
- +11.0%
- 52W High
- $2.86
- 52W Low
- $1.32
- 50D MA
- $1.90
- 200D MA
- $1.91
- Beta
- 1.62
- RSI (14)
- 38
- Avg Volume
- 2.69M
No earnings-call transcripts are available for PALI yet.
- Free Float
- 96.2%
- Shares Outstanding
- 173.58M
- Float Shares
- 166.93M
of shares held by institutions
95 13F filers
Buy/sell ratio 1.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Soleus Capital Management, L.P. | 13.06M | ▲ 13.06M |
| B Group, Inc. | 11.41M | 0 |
| Ameriprise Financial Inc | 11.08M | ▼ 428.89K |
| Jupiter Topco LLC | 10.69M | ▲ 10.69M |
| Janus Henderson Group Ltd. | 10.69M | ▲ 149.12K |
| Blackrock, Inc. | 10.44M | ▲ 8.56M |
| Octagon Capital Advisors LP | 10.28M | 0 |
| Perceptive Advisors LLC | 8.43M | ▼ 503.08K |
| Ra Capital Management, L.P. | 7.12M | 0 |
| Franklin Resources Inc | 5.79M | 0 |
| Point72 Asset Management, L.P. | 5.25M | ▲ 4.84M |
| Boxer Capital Management, LLC | 4.80M | 0 |
Held by 84 ETFs
Biggest fund positions in PALI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 26 | Williams Donald Allen | buy | 10,000 |
| Oct 1, 26 | Williams Donald Allen | buy | 10,000 |
| Aug 19, 26 | Finley John David | other | 88,400 |
| Aug 19, 26 | Finley John David | other | 88,400 |
| Jul 9, 26 | Baltera Robert Jr. | buy | 25,000 |
| Jul 8, 26 | Baltera Robert Jr. | buy | 20,000 |
| Jul 7, 26 | Baltera Robert Jr. | buy | 30,000 |
| Jul 6, 26 | Baltera Robert Jr. | buy | 20,000 |
| Jul 6, 26 | Jones Mitchell Lawrence | other | 131,167 |
| Jul 6, 26 | Jones Mitchell Lawrence | other | 131,167 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PALI coverage
Recent articles, reports, and earnings notes.
No research on PALI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PALI report →Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts
defenseworld.net · Oct 3
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026
globenewswire.com · Sep 28
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
defenseworld.net · Sep 28
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
marketbeat.com · Sep 27
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
globenewswire.com · Sep 23
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD
globenewswire.com · Sep 22
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
globenewswire.com · Sep 21
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.